MET exon 14 skipping: Definition, Uses, and Clinical Overview

Posted on February 27, 2026 | by drcancer

MET exon 14 skipping Introduction (What it is)

MET exon 14 skipping is a cancer-related change in how the MET gene is “spliced” when cells make MET messenger RNA.
It can lead to abnormal activation of the MET pathway, which can help some tumors grow and spread.
It is most commonly discussed as a molecular biomarker in certain solid tumors, especially non-small cell lung cancer (NSCLC).
In clinical care, it is mainly used to guide targeted therapy selection and clinical trial options.

Why MET exon 14 skipping used (Purpose / benefits)

MET exon 14 skipping is used because it can function as an actionable biomarker—meaning it may identify a tumor biology that can be treated with specific targeted drugs (often called MET inhibitors). In modern oncology, many treatment decisions are increasingly based not only on where the cancer started (lung, breast, etc.) but also on the tumor’s molecular drivers (the genetic or signaling changes helping it grow).

In general terms, the main purposes and potential benefits include:

Refining diagnosis and tumor profiling: It helps clinicians describe a tumor’s molecular subtype, which can matter for prognosis and treatment planning.
Guiding therapy selection: In some clinical contexts, a finding of MET exon 14 skipping can support using a MET-targeted treatment rather than (or before/after) other systemic therapies. Exact sequencing varies by cancer type and stage.
Avoiding ineffective treatments for some patients: When a strong oncogenic driver is present, clinicians may consider therapies that directly address that driver instead of relying only on broader treatments (like chemotherapy). This depends on guidelines, the patient’s health status, and available options.
Supporting clinical trial eligibility: Many trials require proof of specific molecular alterations such as MET exon 14 skipping.
Providing a shared “language” for the care team: Pathologists, medical oncologists, and pharmacists use this biomarker to coordinate care and monitoring.

Indications (When oncology clinicians use it)

Oncology clinicians typically evaluate for MET exon 14 skipping in scenarios such as:

Newly diagnosed or previously treated advanced or metastatic non-small cell lung cancer, where molecular testing is part of standard tumor profiling
NSCLC cases where other common driver alterations are not found, or when broad next-generation sequencing is used upfront
Lung cancers with certain histologies (for example, some sarcomatoid features) where MET alterations may be more common
Solid tumors where comprehensive genomic profiling is being performed to look for actionable targets (use varies by tumor type and institution)
When considering clinical trial enrollment that requires MET pathway alterations
When a clinician is evaluating potential mechanisms of resistance after prior systemic therapy (the exact role varies by case)

Contraindications / when it’s NOT ideal

MET exon 14 skipping is a biomarker finding, not a treatment or procedure by itself, so it does not have “contraindications” in the same way a drug or surgery does. However, there are situations where testing for it—or acting on the result—may be less suitable or may require a different approach:

Insufficient tumor material from a biopsy, or poor-quality samples, which can limit accurate molecular testing
Testing method limitations: Some assays may miss certain splice-site changes if they are not designed to detect them; in those cases, RNA-based testing or a different platform may be preferred
Very early-stage disease where tumor profiling may not change immediate management (varies by cancer type and stage, and by clinician and case)
Rapidly changing clinical status where immediate treatment is needed and molecular results are pending; clinicians may start a broader therapy while awaiting results (approach varies)
When a MET-targeted therapy is not appropriate due to patient-specific factors (for example, contraindicated drug interactions, intolerance, or organ dysfunction). These considerations apply to treatment selection, not to the biomarker itself.
Conflicting or unclear results (for example, low tumor DNA in blood testing), where confirmatory tissue testing may be needed

How it works (Mechanism / physiology)

MET exon 14 skipping involves tumor biology rather than a direct “mechanism of action” like a medication. The key concept is gene splicing—the process cells use to turn a gene’s initial RNA copy into a final message (mRNA) that can be translated into a protein.

At a high level:

The MET gene encodes the MET receptor tyrosine kinase, a protein on the cell surface that can transmit growth and survival signals into the cell.
Exon 14 is a segment of the MET gene that contributes to a regulatory region of the MET protein.
When exon 14 is “skipped” during splicing, the resulting MET protein can lose part of its normal regulation. A commonly taught concept is that this change can reduce normal receptor downregulation (the cell’s ability to tag and break down the receptor), leading to more sustained MET signaling.
Increased MET pathway signaling can promote tumor behaviors such as cell growth, survival, invasion, and metastasis, depending on the tumor context.

Onset, duration, and reversibility:

MET exon 14 skipping is not a temporary effect; it is a tumor-associated molecular alteration.
Its clinical relevance can change over time as tumors evolve, especially under treatment pressure. Some tumors develop additional alterations that cause resistance to targeted therapy, which is one reason repeat testing may be considered in selected situations (varies by clinician and case).
The closest “duration” concept is the durability of response to MET-targeted therapy when used, which varies by cancer type and stage and by individual tumor biology.

MET exon 14 skipping Procedure overview (How it’s applied)

MET exon 14 skipping is not a procedure performed on the body. Instead, it is a laboratory result obtained through tumor molecular testing. A typical high-level workflow in oncology looks like this:

Evaluation / exam
A clinician evaluates symptoms, imaging findings, and overall health, and determines whether cancer is suspected or confirmed.
Imaging / biopsy / labs
– Imaging (such as CT, MRI, or PET/CT) may identify a mass or sites of spread.
– A biopsy or surgical specimen provides tissue for pathology and molecular testing.
– In some cases, a blood-based “liquid biopsy” is used to look for tumor DNA in the bloodstream, especially when tissue is limited.
Diagnosis and staging
Pathology confirms cancer type, and staging describes how far it has spread. Staging systems and terminology vary by cancer type.
Molecular profiling (where MET exon 14 skipping is assessed)
The tumor sample (tissue and/or blood) is tested using methods such as next-generation sequencing (NGS). The lab reports whether MET exon 14 skipping is detected and may also report other relevant alterations.
Treatment planning
The care team integrates staging, overall health, and molecular results to choose among systemic therapy, local therapy (surgery/radiation), supportive care, or clinical trials. The role of MET-targeted therapy varies by cancer type and stage.
Intervention / therapy
If a MET-targeted treatment is chosen, it is typically a systemic therapy (often oral). Some patients may receive chemotherapy, immunotherapy, radiation, surgery, or combinations/sequences.
Response assessment
Clinicians monitor symptoms, imaging, and lab tests to assess response and side effects. The timing and tools used depend on the clinical context.
Follow-up / survivorship
Follow-up focuses on surveillance for recurrence or progression, management of long-term effects, and supportive services (rehabilitation, nutrition, psychosocial care). Needs vary widely.

Types / variations

MET exon 14 skipping can be discussed in several “types” or variations, mainly based on how it arises and how it is detected:

Different underlying DNA changes leading to the same skipping event
The exon is skipped because of mutations around splice sites or within regulatory regions. Multiple distinct DNA alterations can produce the same functional outcome: loss of exon 14 from the final MET mRNA.
DNA-based vs RNA-based detection
DNA-based NGS looks for genomic changes near splice sites that are predicted to cause exon skipping.
RNA-based testing looks more directly at the final transcript and can confirm that exon 14 is actually absent in the expressed mRNA.
Which approach is used depends on lab capability, tissue availability, and clinical preference.
Tissue biopsy vs liquid biopsy
Tissue testing can be more comprehensive in some situations because it directly analyzes tumor cells.
Liquid biopsy is less invasive and can be useful when tissue is hard to obtain, but it may miss alterations if there is low tumor DNA in the blood.
MET exon 14 skipping with or without other MET changes
Some tumors may also show MET amplification (extra copies of the MET gene) or other co-alterations. These combinations can influence tumor behavior and treatment response, but effects vary by case.
Primary driver vs part of a complex profile
In some cancers, MET exon 14 skipping behaves like a key driver alteration. In other settings, it may appear alongside multiple changes, making treatment decisions more nuanced.

Pros and cons

Pros:

Helps identify an actionable molecular target in some cancers
Supports more personalized treatment selection when targeted options are available
Can be detected through broad NGS panels, which also assess other important biomarkers
May reduce trial-and-error by clarifying whether a MET-targeted approach is reasonable (depends on cancer type and stage)
Can inform clinical trial eligibility and access to emerging therapies
Provides a biologically grounded explanation for tumor behavior in some cases

Cons:

Detection can be technically challenging, especially if the assay is not optimized for splice alterations
False negatives can occur with low tumor content, poor sample quality, or low circulating tumor DNA in blood testing
Presence of MET exon 14 skipping does not guarantee response; outcomes vary by cancer type and stage and by co-alterations
Targeted therapies can have side effects and monitoring needs (type and severity vary by drug and patient)
Tumors can develop resistance mechanisms, which may limit duration of benefit
Access to comprehensive testing and targeted treatments can vary by region, health system, and insurance coverage

Aftercare & longevity

Because MET exon 14 skipping is a test result rather than a procedure, “aftercare” usually refers to the follow-up after:

a biopsy or blood draw used for testing, and/or
the systemic therapy chosen based on results.

In general, what affects outcomes and longevity includes:

Cancer type and stage at diagnosis: Earlier-stage cancers may be managed with local therapies, while advanced cancers often require systemic treatment.
Overall tumor biology: Co-existing mutations, MET amplification status, and how dependent the tumor is on MET signaling can influence response.
Treatment selection and sequencing: Some patients may receive targeted therapy first, while others receive it later; practices vary by clinician and case.
Tolerance and adherence: Side effects can lead to dose changes or interruptions, which may affect effectiveness.
Monitoring and follow-up: Regular assessment with imaging and labs helps evaluate response and detect complications. The schedule varies.
Supportive care: Managing symptoms (fatigue, appetite changes, swelling, nausea, pain), maintaining nutrition, and addressing emotional health can affect function and quality of life.
Comorbidities and medications: Heart, lung, kidney, or liver conditions—and drug interactions—can shape safe treatment choices.
Rehabilitation and survivorship services: Physical therapy, pulmonary rehab, psychosocial support, and palliative care (when appropriate) can improve day-to-day well-being regardless of stage.

Alternatives / comparisons

MET exon 14 skipping is most useful as a decision-making biomarker. Alternatives and comparisons usually relate to (1) how testing is performed and (2) what treatments are used if the alteration is present or absent.

High-level comparisons include:

Broad NGS profiling vs single-gene testing
Broad NGS can detect multiple driver alterations at once, which is helpful because treatment options may depend on the full profile.
Single-gene approaches may be faster or cheaper in some settings but can miss other important targets.
Tissue testing vs liquid biopsy
Tissue testing can provide tumor architecture and confirm diagnosis, with molecular testing performed on the same sample.
Liquid biopsy can be a practical alternative when tissue is limited, but a negative result may not rule out an alteration.
Targeted therapy vs chemotherapy
Targeted therapies aim at a specific driver pathway (like MET) and may be used when the tumor has the relevant alteration.
Chemotherapy affects rapidly dividing cells more broadly and may be used alone or in combination depending on cancer type and stage.
Targeted therapy vs immunotherapy
Immunotherapy can be effective in many cancers, but response varies. For some oncogenic drivers, clinicians carefully consider how to sequence immunotherapy and targeted therapy due to differences in expected benefit and side-effect profiles. Exact decisions vary by clinician and case.
Standard care vs clinical trials
Clinical trials may offer access to next-generation MET inhibitors or combination strategies, particularly when standard options have been used or resistance develops.
Trial suitability depends on eligibility criteria, prior treatments, organ function, and performance status.
Local therapy (surgery/radiation) vs systemic therapy
Local therapy may be central in early-stage disease or for symptom control in selected metastatic settings.
Systemic therapy is typically needed when disease is widespread, regardless of biomarker status.

MET exon 14 skipping Common questions (FAQ)

Q: Is MET exon 14 skipping the same as a MET mutation?
MET exon 14 skipping is often caused by DNA changes near splice sites, so it is related to mutations, but the defining feature is the splicing outcome—exon 14 is omitted from the MET mRNA. Clinicians may use terms like “METex14” as shorthand. The lab method used can affect how the result is reported.

Q: How is MET exon 14 skipping tested for?
It is usually detected through molecular testing such as next-generation sequencing on tumor tissue. In some cases, it can be detected through a blood-based liquid biopsy that looks for tumor DNA. Sometimes RNA-based testing is used to more directly confirm the exon-skipping event.

Q: Does testing hurt, and will I need anesthesia?
The testing itself is done in a laboratory. Discomfort depends on how the sample is collected: a blood draw is typically brief, while a tissue biopsy may involve local anesthesia, sedation, or other pain-control methods depending on the biopsy site and technique. Your clinical team typically explains expected sensations and recovery for the specific sampling approach.

Q: If MET exon 14 skipping is found, does that mean targeted therapy will definitely work?
Not necessarily. This biomarker can indicate that MET signaling is important in a tumor, but response varies by cancer type and stage and by additional tumor features. Even with an initial response, some tumors later develop resistance.

Q: What side effects can happen with MET-targeted treatments?
Side effects vary by specific drug and individual factors. Examples that clinicians commonly monitor for include swelling (edema), nausea, diarrhea or constipation, fatigue, appetite changes, and changes in liver blood tests. Rare but potentially serious lung inflammation has been reported with some targeted therapies, so new or worsening breathing symptoms are usually evaluated promptly by the care team.

Q: How long does treatment last if a MET inhibitor is used?
Duration is individualized and depends on response, side effects, and the overall treatment plan. In advanced cancer, targeted therapy may continue as long as it is helping and tolerable, but this varies by clinician and case. Some people may switch therapies if the cancer changes or if side effects become limiting.

Q: Will I be able to work or do normal activities during treatment?
Many people can continue some daily activities, but energy levels and side effects vary widely. Swelling, fatigue, and gastrointestinal effects can affect comfort and mobility. Clinicians often adjust supportive care and, when needed, modify dosing to balance treatment and daily function.

Q: What does a negative result mean—does it rule out MET involvement?
A negative result means MET exon 14 skipping was not detected by that test in that sample. It may be truly absent, or it may be missed due to low tumor content, technical limits of the assay, or low circulating tumor DNA in blood testing. When results do not fit the clinical picture, clinicians sometimes consider repeat or alternative testing methods.

Q: Is MET exon 14 skipping inherited, and does it affect family members?
In most cases, MET exon 14 skipping is considered a somatic alteration, meaning it arises in tumor cells and is not inherited. However, genetics can be complex, and clinicians may recommend genetic counseling when there are features suggesting an inherited cancer syndrome. The decision to pursue germline testing depends on personal and family history and tumor findings.

Q: What about fertility and pregnancy concerns?
Fertility and pregnancy considerations depend on the overall cancer treatment plan, the specific drugs used, and the patient’s circumstances. Some systemic therapies may pose risks to a developing pregnancy or may affect fertility potential. Oncology teams commonly discuss fertility preservation and contraception considerations before starting systemic treatment, when relevant.